• “COVID-19 More Severe for Patients with Pre-existing Conditions”

    “Young, Healthy People at Less Risk of Severe Complications from COVID-19”

    As members of the global MEN community, these kinds of headlines can be frightening and lead to unanswered questions such as “Am I at greater risk of getting COVID-19 because of my MEN treatments?” or “Does hypercalcemia count as a pre-existing condition?”.

    AMEND USA board members Jo Grey, John Metzcar, and Mary Metzcar reached out to medical experts and researchers Dr. Jenny Blau, Dr. Electron Kebebew, and Dr. Jaydira Del Rivero to seek answers to some of these common COVID-19 questions from the MEN community.

    Responses have been paraphrased for brevity.

  • As an MEN patient who has neuroendocrine tumors now or had them in the past, is it safe to receive a COVID-19 vaccine? What if I am under treatment, recently received treatment, or am about to receive treatment for neuroendocrine tumors?

  • What are the general risk factors for COVID-19 and how do they overlap with medical conditions associated with MEN disorders?

  • How do I reduce my risk of catching or spreading the coronavirus?

  • Are members of the MEN population at greater risk of getting COVID-19 or of having its more severe consequences?

  • I am in treatment for neuroendocrine tumors. Should I be more concerned about COVID-19?

  • I recently underwent surgery. Is there anything special I should do because of COVID-19?

  • I use steroids as part of my MEN treatment plan. Does this put me at an increased risk for getting COVID-19 or for having a more severe illness?

  • I am on dopamine agonists because of a pituitary adenoma. Am I at an increased risk?

  • I have high or low calcium because of parathyroid tumors. Am I at an increased risk?

  • I have “active” pheochromocytoma. Am I at an increased risk of catching COVID-19?

  • I have medullary thyroid cancer, and I’m currently receiving treatments. Am I at an increased risk for complications of COVID-19?

  • My thymus was removed during a parathyroid surgery. I’ve read that the thymus is part of the immune system. Do I have a weakened immune system that is more likely to catch COVID-19?

  • I have MEN2 and have not yet had thyroid surgery. How urgent is thyroid surgery right now?

  • What changes in monitoring might patients expect during this time of increased uncertainty?

  • How do I stay prepared in case I need to quarantine?

  • What do I do if I develop symptoms of COVID-19?

  • If I do catch COVID-19, are there any special considerations considering I have an MEN disorder?

  • What are other recommended COVID-19 resources for the MEN community?

  • Jenny E. Blau, MD
    At the time this article was originally published, Dr. Blau was a researcher and director of the Calcium and MEN1 Clinical Studies Unit at the National Institute of Diabetes and Digestive and Kidney Diseases. She studied inherited syndromes that are associated with hyperparathyroidism, including multiple endocrine neoplasia type 1 (MEN1). Her research aimed to translate molecular mechanisms by which this inherited syndrome can lead to neoplasia (tumors) into improved treatments for patients.

    Electron Kebebew, MD, FACS
    https://profiles.stanford.edu/electron-kebebew
    Dr. Kebebew is a professor and chief at Stanford University in the department of general surgery. He is an internationally recognized expert in Endocrine Oncology and Surgery. He has performed more than three thousand operations on the adrenal, parathyroid and thyroid glands, and for neuroendocrine tumors of the gastrointestinal tract and pancreas.

    Jaydira Del Rivero, MD
    https://ccr.cancer.gov/staff-directory/jaydira-del-rivero
    Dr. Del Rivero is an endocrine oncologist in the Pediatric Oncology Branch of the Center for Cancer Research within the National Cancer Institute. She works on tumor immunology and the development of novel immunotherapy approaches for medullary thyroid cancer and targeted therapies for other endocrine malignancies such as advanced pheochromocytoma/paraganglioma.